Clinical Trials
273
Active:267
Completed:4
Trial Phases
3 Phases
Phase 1:234
Phase 3:5
Phase 4:2
Drug Approvals
21
FDA:17
NMPA:3
SFDA:1
Drug Approvals
Avalglucosidase Alfa for Injection
- Product Name
- 耐而赞
- Approval Number
- 国药准字SJ20230015
- Approval Date
- Sep 28, 2023
NMPA
Cross-linked Sodium Hyaluronate Injection
- Product Name
- 欣维可
- Approval Number
- 国药准字HJ20160580
- Approval Date
- Jul 29, 2021
NMPA
Cross-linked Sodium Hyaluronate Injection
- Product Name
- 欣维可
- Approval Number
- 国药准字HJ20160464
- Approval Date
- Jul 29, 2021
NMPA
Clinical Trials
Distribution across different clinical trial phases (241 trials with phase data)• Click on a phase to view related trials
Phase 1
234 (97.1%)Phase 3
5 (2.1%)Phase 4
2 (0.8%)No trials found
News
BioCryst Names Charlie Gayer as New CEO Following Jon Stonehouse's Retirement Announcement
BioCryst Pharmaceuticals announced that CEO Jon Stonehouse will retire on December 31, 2025, with current Chief Commercial Officer Charlie Gayer set to succeed him as president in August and CEO in January 2026.
Crescent Biopharma Appoints Jan Pinkas as Chief Scientific Officer to Advance Oncology Pipeline
Crescent Biopharma has appointed Jan Pinkas, Ph.D., as chief scientific officer, bringing over two decades of oncology drug development experience including expertise in antibody-drug conjugates.